Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...

TOKYO, Feb 5 (Reuters) - Marubeni (8002.T), opens new tab said on Wednesday it is aiming for a net profit of more than 620 billion yen ($4 billion) in fiscal 2027/2028 along with a 40% total ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker. OSAKA, Japan & CAMBRIDGE, Mass., January 30, 2025--Takeda ...

See Correction/Clarification at the end of this article. After layoffs in 2024, Takeda is gearing up for a big 2025 that includes preparations to launch three new medicines, hiring, and finishing ...

Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical (4502.T), opens new tab, is looking to raise $149 million by offering about 7.3 million American depositary shares at $20.34 each.

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...

SYDNEY -- Australia's Queensland state government said on Monday it will halt further investment in a hydrogen project that includes Japanese trading house Marubeni, amid mounting headwinds ...

TOKYO -- Japanese trading house Marubeni has agreed to invest in Phillips Pharma Group, which supplies medical goods in sub-Saharan Africa. The investment marks Marubeni's entry into the African ...